Alpha Teknova prices $40M stock offering at $5
Teknova's preliminary third-quarter estimates include 19%–21% year-over-year revenue growth and $16.6 million in cash and short-term investments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alpha Teknova, Inc. (TKNO) priced an underwritten public offering of 8,000,000 common shares at $5.00 per share, with expected gross proceeds of $40 million before discounts, commissions and expenses. Underwriters agreed to purchase the shares at $4.70 each and received a 30-day option to buy up to 1,200,000 additional shares. The offering is expected to close on or about October 22, 2026, subject to customary closing conditions. Net proceeds are intended for general corporate purposes, potentially including debt repayment; a portion may be used for acquisitions or investments, though the company has no current commitments or arrangements. Directors and executive officers entered into lock-up agreements generally restricting transfers before January 19, 2027, subject to exceptions and prior written consent.
For the three months ended September 30, 2026, Teknova preliminarily estimated revenue of $12.5 million to $12.7 million, gross margin of 36.0% to 38.0%, and an Adjusted EBITDA loss of $1.2 million to $1.0 million. Cash and short-term investments were estimated at $16.6 million as of September 30, 2026. The company also stated estimated year-over-year revenue growth of 19% to 21%, gross-margin expansion of 500 to 700 basis points, and an Adjusted EBITDA loss improvement of at least 25%. These preliminary estimates are subject to quarterly review and may change materially.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointPreliminary Q3 revenue growth: 19%–21% year over year.
- Moderate pointEstimated gross-margin expansion: 500–700 basis points year over year.
- Moderate pointEstimated Adjusted EBITDA loss improvement: at least 25% year over year.
Negative
- None.
Filing Explained
The underwriters agreed to buy 8 million shares, but the sale has not closed and is expected on or about October 22, subject to conditions; if completed, issuance increases the share count and reduces existing holders’ ownership percentages, with up to 1.2 million more shares possible under the option.
8-K Event Classification
Key Figures
Key Terms
underwritten public offering financial
gross proceeds financial
Adjusted EBITDA financial
Free Cash Outflow financial
Earnings Snapshot
Fiscal 2026 revenue of $45 million to $47 million; Free Cash Outflow of less than $8 million.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were TKNO's preliminary Q3 2026 results?
What is TKNO's 2026 revenue guidance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| (Title of each class) |
(Trading Symbol) |
(Name of exchange on which registered) | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 1.01. | Entry into a Material Definitive Agreement. |
On October 20, 2026, Alpha Teknova, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and William Blair & Company, L.L.C. as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of an aggregate of 8,000,000 shares of the Company’s common stock (“Common Stock”). The public offering price is $5.00 per share of Common Stock and the Underwriters have agreed to purchase the shares of Common Stock pursuant to the Underwriting Agreement at a price of $4.70 per share of Common Stock. Under the terms of the Underwriting Agreement, the Company also granted to the Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to 1,200,000 additional shares of Common Stock.
The Offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-288613), previously filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025, and declared effective on July 16, 2025, a base prospectus dated July 16, 2025 and a prospectus supplement dated October 21, 2026.
Gross proceeds from the Offering will be $40 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. The Company may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although the Company has no current commitments or arrangements to do so. The purchase and sale of the shares of Common Stock and the closing of the Offering, are expected to take place on or about October 22, 2026, subject to the satisfaction of customary closing conditions.
The Underwriting Agreement contains customary representations, warranties and covenants made by the Company. It also provides for customary indemnification by each of the Company and the Underwriters, severally and not jointly, for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, each of the Company’s directors and executive officers has entered into “lock-up” agreements with TD Securities (USA) LLC and William Blair & Company, L.L.C., which generally prohibit, without the prior written consent of TD Securities (USA) LLC and William Blair & Company, L.L.C. and subject to certain exceptions, the sale, transfer or other disposition of securities of the Company prior to January 19, 2027.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Underwriting Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Underwriting Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K. A copy of the opinion of Paul Hastings LLP, counsel to the Company, relating to the validity of the shares of Common Stock to be issued in the Offering is filed herewith as Exhibit 5.1.
| Item 2.02 | Results of Operations and Financial Condition. |
Financial Update
On October 20, 2026, the Company estimated that its revenue for the three months ended September 30, 2026 was between approximately $12.5 million and $12.7 million, with a gross margin of between 36.0% and 38.0%. The Company also estimated that as of September 30, 2026, it had $16.6 million in cash and short term investments. Further, the Company estimated that its Adjusted EBITDA for the three months ended September 30, 2026 was between negative $1.2 million and negative $1.0 million.
The Company’s financial statements for the three months ended September 30, 2026 are not yet available. Accordingly, the information presented above reflects the Company’s preliminary estimates subject to the completion of the Company’s financial closing procedures and any adjustments that may result from the completion of the quarterly review of the Company’s financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in the Company’s financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material.
The Company’s expectations with respect to its unaudited results for the period discussed above are based upon management estimates and are the responsibility of management. The Company’s independent registered public accounting firm has not audited, reviewed, or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them.
Reconciliation of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP financial measure that is not prepared in accordance with GAAP and that may be different from non-GAAP financial measures used by other companies. Our management believes that the use of this non-GAAP financial measure provides an additional tool for investors to use in evaluating ongoing operating results and trends of the Company. This non-GAAP financial measure should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Adjusted EBITDA is a non-GAAP financial measure equal to net loss, the most directly comparable financial measure based on GAAP, excluding interest expense, income tax expense, depreciation and amortization, and stock-based compensation expense.
The following is a reconciliation of net income, the most directly comparable GAAP financial measure to Adjusted EBITDA:
| ($ in thousands) |
Three Months Ended | |
| Net loss |
$(3,694) - $(3,494) | |
| Add back: |
||
| Interest expense, net |
(259) | |
| Provision for income taxes |
34 | |
| Depreciation expense |
1,302 | |
| Amortization of intangible assets |
287 | |
|
| ||
| EBITDA |
$(1,812) - $(1,612) | |
|
| ||
| Other and non-recurring expenses: |
||
| Stock-based compensation expense |
612 | |
|
| ||
| Adjusted EBITDA |
$(1,200) - $(1,000) | |
|
|
| Item 8.01. | Other Events. |
On October 20, 2026, the Company issued a press release announcing the launch of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
On October 20, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
On October 21, 2026, the Company posted an updated company presentation to the investor section of the Company’s website. A copy of this presentation is attached as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit |
Description | |
| 1.1 | Underwriting Agreement, dated as of October 20, 2026, by and among Alpha Teknova, Inc., TD Securities (USA) LLC and William Blair & Company, L.L.C. | |
| 5.1 | Opinion of Paul Hastings LLP. | |
| 23.1 | Consent of Paul Hastings LLP (included in Exhibit 5.1). | |
| 99.1 | Launch Press Release, dated October 20, 2026. | |
| 99.2 | Pricing Press Release, dated October 20, 2026. | |
| 99.3 | Company Presentation, dated October 14, 2026. | |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). | |
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1955 that involve risks and uncertainties, such as statements related to the anticipated closing of the Offering and the anticipated use of proceeds from the Offering. The risks and uncertainties involved include the Company’s ability to satisfy certain conditions to closing the Offering on a timely basis or at all, market conditions and other risks detailed from time to time in the Company’s periodic reports and other filings with the SEC. Forward-looking statements can often be identified by words such as “will,” “intends,” “potentially,” “may,” “expect,” and similar expressions, and variations and negatives of these words. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. Readers should not place undue reliance on any forward-looking statements, and are encouraged to review the Company’s other filings with the SEC for a more complete discussion of risks and other factors that could affect any forward looking statement. The Company does not intend to revise or update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALPHA TEKNOVA, INC. | ||||||
| Date: October 21, 2026 | By: | /s/ Stephen Gunstream | ||||
| Name: | Stephen Gunstream | |||||
| Title: | President and Chief Executive Officer | |||||
Exhibit 99.1
Teknova Announces Proposed Public Offering of Common Stock
HOLLISTER, CA – October 20, 2026 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
TD Cowen and William Blair are acting as joint book-running managers for the proposed offering.
Teknova currently intends to use the net proceeds from the proposed offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so.
The proposed offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-288613), previously filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025, and declared effective on July 16, 2025. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may also be obtained by contacting TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the timing, size and completion of the proposed offering, Teknova’s intention to grant the underwriters a 30-day option to purchase additional shares, and the anticipated use of proceeds therefrom. Forward-looking statements can often be identified by such words as “will,” “expects,” “plans,” “believes,” “intends,” “estimates,” “projects,” “continue,” “potential” or other similar words or expressions. Forward-looking statements are based on Teknova’s current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law.
Contacts:
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Exhibit 99.2
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
HOLLISTER, CA – October 20, 2026 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions.
TD Cowen and William Blair are acting as joint book-running managers for the proposed offering. Craig-Hallum is acting as lead manager. Stephens Inc. and Roth Capital Partners are acting as co-managers. Perrella Weinberg Partners is serving as financial adviser to Teknova.
Teknova currently intends to use the net proceeds from this offering for general corporate purposes, including potentially the repayment of outstanding debt obligations. Teknova may use a portion of the net proceeds to acquire or invest in other businesses, products, and technologies that are complementary to its own, although Teknova has no current commitments or arrangements to do so.
The public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-288613), previously filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025, and declared effective on July 16, 2025. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering, may also be obtained by contacting TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at TDManualrequest@broadridge.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687, or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. Forward-looking statements can often be identified by such words as “will,” “expects,” “plans,” “believes,” “intends,” “estimates,” “projects,” “continue,” “potential” or other similar words or expressions. Forward-looking statements are based on Teknova’s current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law.
Contacts:
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Exhibit 99.3 Making Solutions Possible COMPANY OVERVIEW October 2026
Forward-looking statements and use of non-GAAP financial measures This meeting is for the purpose of familiarizing you with Alpha Teknova, Inc. ( Teknova ) and is made for informational purposes only and nothing in the presentation should be viewed, or construed, as “advice”. You understand and agree that the fact this meeting has taken place and anything you hear or learn during this meeting is strictly confidential. By agreeing to attend this meeting, you agree to keep all such information confidential. We have filed with the Securities and Exchange Commission (the SEC ) a registration statement on Form S-3 (including a prospectus) and will file with the SEC a prospectus supplement to the prospectus for the proposed public offering of our securities to which this presentation (and oral statements made regarding the subjects of this presentation) relates. Before you invest, you should read the prospectus supplement and accompanying prospectus in that registration statement and the documents incorporated by reference or filed as exhibits to the registration statement for more complete information about the Company and this offering. You may obtain these documents, when available, and other documents for free by visiting EDGAR on the SEC website. Alternatively, copies of the prospectus supplement and accompanying prospectus, when available, may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, or by telephone at (855) 495-9846 or email at TD.ECM_Prospectus@tdsecurities.com; or from William Blair & Company, L.L.C., The William Blair Building, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at (800) 621-0687 or email at prospectus@williamblair.com. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws. Additionally, this presentation contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow). Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance. Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment. Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this presentation because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies. A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this presentation. 2 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics 2026E REVENUE GROWTH PROJECT ADJUSTED 2026E REVENUE GUIDANCE (MIDPOINT) EBITDA POSITIVE QTR IN 14% 2027 $45-47M ACTIVE # CLINICAL CUSTOMER NUMBER OF CUSTOMERS 2025 YoY % GROWTH THERAPIES SUPPORTED 3,000+ 25% >70 CUSTOMER NUMBER OF ASSOCIATES % REVENUE RETENTION RATE (AS OF JUNE 30, 2026) FROM CELL & GENE THPY 95% 156 ~24% All metrics reflect FY:2025 actuals unless otherwise noted. 2026 figures are guidance/estimates and subject to change. © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 3
Our products are foundational to the life sciences industry LIQUID MICROBIAL MOLECULAR AGAR PLATES CULTURE MEDIA BIOLOGY REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Vast range of product types, sizes, and specialty pre-poured agar and broths to expand a particular pH, and molarities to support a plates for a wide variety of microbial or bacterial cell of multitude of applications, such as applications including bacteria, interest under controlled cell lysis, purifying nucleic acids or fungi, and nematode growth, conditions, to freeze cells, or to proteins, washing, resuspending, and environmental monitoring conduct media fills for aseptic and analyzing samples, and in cleanroom spaces validation and monitoring sample management © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 4
2025 REVENUE BREAKDOWN Primary End Markets 5% Non- Product Revenue APPROX. APPROX. APPROX. 400 1,900 1,000 ~15% ACCOUNTS ACCOUNTS ACCOUNTS Other Markets BIOPHARMA AND LIFE SCIENCE TOOLS OTHER MARKETS CONTRACT AND DIAGNOSTICS MANUFACTURING ~50% Biopharma & Contract ~30% • ~850 Biotech • ~250 Life Science Tools • Academic & Government Manufacturing Life Science • Animal Health • ~30 Large Pharma • ~150 Diagnostic Tools & • Hospitals • ~200 CDMO/CMOs Diagnostics • Distributors REVENUE BY END MARKET: FY:2025 5 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026
Revenue by Product Type and Customer End Market Total 2024 Revenue by OTHER Product Type and End Market 2025 REVENUE BREAKDOWN ~5% CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS § Research-grade reagents (RUO) ~20% 15% § Catalog product revenue comprises ~80% CLINICAL SOLUTIONS Catalog § Custom product revenue comprises ~20% CUSTOM <5% PRODUCTS (including RUO+) • Primarily Biopharma, Life Science Tools 60% and Diagnostics customers 15% LAB ESSENTIALS LAB ESSENTIALS CATALOG PRODUCTS • Clinical Solutions: ~20% of 2025 Revenue CUSTOM PRODUCTS § Clinical-grade reagents (GMP) § Catalog product revenue comprises ~10% LAB § Custom product revenue comprises ~90% ESSENTIALS • Primarily Biopharma and Diagnostics ~75% customers in clinical trials • Other: ~5% of 2025 Revenue § Includes services, shipping, and other non-product related revenue © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 6
Why We Win FASTER CATALOG BUSINESS SMALLER CUSTOM TURNAROUND TIME AS A FOUNDATION BATCH SIZES Initial Build Sizes for Custom Time from Order to Shipment Relative Annual Spend Research and Clinical Orders by Account Type in 2025 for Custom Orders 44X 10,000 L MONTHS 1,000 L Typical batch size for Emerging Therapies 100 L 25X and Diagnostics PRODUCTS SHIPPED IN WEEKS 10 L 1 L 1X 1 Others Teknova Catalog Custom GMP 1 Only RUO Others Teknova 1 Illustrative models based on Teknova’s knowledge of competing technologies © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 7 TIME Quote Production QC
The barriers to producing similar custom reagents for our target markets are considerable FACILITIES AND ESTABLISHED CO-LOCATED BESPOKE MODULAR INFRASTRUCTURE CATALOG BUSINESS MANUFACTURING SYSTEM Estimated Cost to Replicate: Estimated Time to Replicate: Estimated Time to Replicate: * * * $50M+, >3 years >10 years >5 years • State-of-the-art, GMP • Switch seamlessly between • Specialized, in-house built manufacturing facilities production of catalog and software and equipment custom products • Facilities support production • Custom integration of key IT needs from discovery to • On-site access to raw materials systems: ERP, QMS, and CRM commercialization due to breadth of catalog • Proprietary production know-how • Capacity for >$200M in annual • Effective utilization of key costs learned over 30 years across * revenue like labor, equipment, and facilities thousands of SKUs * Based on management’s estimates © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 8
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 9
Continued success in attracting clinical customers 1 NUMBER OF CLINICAL SOLUTIONS CUSTOMERS 60 10 48 6 35 7 26 23 50 4 42 6 13 36% 28 2 22 17 2020-2025 11 CAGR 2020 2021 2022 2023 2024 2025 Biopharma Tools/Dx/Other Total 1 Customer is defined as any customer purchasing within the fiscal year. There is a $5,000 minimum threshold for Clinical Solutions customers. © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 10
We are a critical supplier for more than 70 therapies in clinical trials ~$3.0M ~$0.3M 29.8X ~$0.2M ~$0.1M 3.2X 1.4X 1X Illustrative Annual and Relative 1 Customer Spend by Phase CLINICAL DEVELOPMENT RESEARCH PRECLINICAL POST-APPROVAL AND DISCOVERY DEVELOPMENT PHASE Stage of Clinical Therapies Supported EXPECT TO 55+ 12 5 SUPPORT AT LEAST ONE PRECLINICAL PHASE 1 PHASE 2/3 COMMERCIAL THERAPY OR DIAGNOSTIC BY END OF 2027 1 Fletcher Spaght Growth Strategy Report, commissioned by Teknova and dated October 6, 2020 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 11
Life Science Tools and Diagnostics accounts comprise remaining Clinical Solutions customers These customers utilize Teknova to manufacture their proprietary formulations for resale or as raw materials in their manufacturing processes to support high growth end markets such as bioprocessing and liquid biopsy © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 12
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 13
Supporting 3,000+ customers across the life sciences Limited Customer Concentration Stable Top Accounts (Top Lab Essentials Revenue / Total Revenue) 2025 End Market Tenure 2019-25 CAGR Rank 1 Genomics >10 yrs 45% Top 5: 12% 42% 2 Genomics >10 yrs Top 10: 18% 72% 3 Genomics 9 yrs 4 Large Pharma >10 yrs 10% 10% 5 Genomics >10 yrs 6 Cell & Gene Therapy 9 yrs 91% 6% 7 Distributor >10 yrs Rest: 82% 8 Large Pharma >10 yrs 9% 0% 9 CDMO >10 yrs 10 Cell & Gene Therapy >10 yrs -19% © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 14
Our products are foundational to the life sciences industry Plasmid Production Gene DNA We support the leading life Synthesis and RNA science tools companies: • Sequencing • Single cell Spatial- Enzyme • Spatial genomics genomics Production • Enzyme production • Nucleic acid production Single- Sequencing Cell Analysis © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 15
History of consistent double-digit growth LAB ESSENTIALS REVENUE $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 11% $10,000,000 2008-2025 $5,000,000 CAGR $- 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Pandemic © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 16
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 17
Over $200M in revenue * capacity with minimal additional capital investment required • ISO 13485-certified (GMP) facilities to support customers from discovery to commercialization 2 • Over 180,000 ft of facilities, including 2 approximately 10,000 ft of ISO 7 cleanrooms • In-house automation, engineering, and software teams support development and implementation of new production lines • Set up to scale with custom implementations of ERP, Quality Management System, Salesforce, and data analytics * Based on management’s estimates © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 18
FTEs (#) Effective cost management after period of investment sets up attractive financial profile with top-line growth $45 300 $41 $41 $35 $38 $37 250 $25 200 $15 ADJUSTED EBITDA 150 POSITIVE QTR $5 BEFORE THE END OF 100 ($7) ($5) ($15) 50 ($15) ($20) 2027 ($22) ($25) 0 2022 2023 2024 2025 Revenue Adj.EBITDA FTEs © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 19 MILLIONS ($)
SIGNIFICANT OPERATING LEVERAGE WITH TOP-LINE GROWTH 70% of revenue growth drops to bottom line 65%+ Gross Margin Gross Profit Variable Cost of Goods Sold • Grows in proportion to revenue – direct materials, packaging, scrap/waste, supplies, etc. • ~25-30% of total cost of sales today 55-60% Gross Margin Fixed Cost of Goods Sold • Largest component of our cost of 33% 27% Adj. goods today Gross Margin Gross Margin* • Capacity utilization drives absorption of fixed costs • Efficiencies from automation and higher volumes on GMP product runs allow more dollar output per labor hour 2024 2025 2X Revenue 4X Revenue * Adjusted Gross Margin equals GAAP Gross Margin plus $2.8M non-recurring non-cash charge for expired and excess inventory. © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 20
Key Takeaways Research- Significant Critical grade Additional operating supplier of reagents near-term leverage in GMP-grade provide a catalysts our P&L reagents diverse, create as our for emerging predictable, potential revenue therapies and and growing tailwinds increases diagnostics foundation © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 21
NEAR-TERM CATALYST Investing in commercial capabilities and activities INVESTMENT ($2M) SITUATION 1. Expand field team with expertise in life science • We believe that Biopharma end markets have stabilized and tools, diagnostics, and large pharma higher funding levels will persist 2. Drive more brand awareness through marketing activities such as tradeshows, seminars, and • We have also seen traction in targeted outreach high-growth markets like sequencing, spatial genomics, 3. Launch new lead generation tools and and cancer screening resources, including custom-built AI database for lead generation and qualification EXPECT INVESTMENT WILL ACCELERATE REVENUE GROWTH IN LATE 2026 AND INTO 2027 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 22
NEW AI-POWERED ASSISTANT TM Build●Tek Custom Configurator Build complex custom product requests in minutes with Teknova’s interactive reagent assistant 3 minutes 3 days 30 years Build a complete Submit your Proven custom custom order with configuration and our reagent manufacturing just a few clicks in team returns a quote in experience behind one guided session 2-3 business days every order Evolution of our original Build●Tek buffer configurator provides complete guidance on formulation, format, manufacturing grade, QC testing, and more: • Assistant is trained on 30 years of Teknova’s manufacturing processes and know-how • Eliminates need for multiple rounds of inputs between the developer and Teknova technical team, which could take weeks and be error-prone • Configurations start with as much – or as little – as the developer has, and supports the upload of existing files, formulations, or literature • Developers can design multiple products at once • Additional features and functionality to come © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 23
NEW MANUFACTURING CAPABILITY TM Fill●Tek Dispensing System Increased customer demand for multiple bag sizes and filling configurations from the same production run led the team to develop our new single-use bag filling process • Provides greater flexibility for more varied custom GMP orders § Removes previous order quantity limitations due to pre-welded manifold • Improves margin for catalog GMP products by reducing costly manufacturing components Supports wide range of filters, and QC sample and product bag sizes (from 250 mL to 200 L single-use bags) Works across multiple bag + connector + tubing types to seamlessly plug into customer’s system Reduces incoming QC requirements for the customer Fully validated for GMP-grade manufacturing, up to 16 welds per line 24 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026
NEAR-TERM CATALYST Historically seen a four-quarter lag between funding changes and effects on revenue 45 6 4-QUARTER 40 SHIFT SITUATION 5 35 • Biotech funding has been mostly down since mid-2022 30 4 • Substantial rebound in funding 25 observed starting in Q4:2025 3 • Strong first half growth in 2026 20 15 2 IMPACT 10 1 Primary impact is in purchases of custom 5 products from Biopharma customers, which represented approximately 25% of - 0 total revenue in 2025 Biotech Funding Custom Biopharma Revenue Custom Biopharma Revenue -4Q © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 25 Q1:19 Q2:19 Q3:19 Q4:19 Q1:20 Q2:20 Q3:20 Q4:20 Q1:21 Q2:21 Q3:21 Q4:21 Q1:22 Q2:22 Q3:22 Q4:22 Q1:23 Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26
NEAR-TERM CATALYST Opportunity to expand through tuck-in M&A Specific areas of interest: • Cell culture media and supplements • Transfection reagents • Cytokines, growth factors, enzymes, antibodies and other proteins • Geographic expansion © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 26
Proven management team with extensive experience in life sciences Stephen Gunstream Matt Lowell Jennifer Henry Damon Terrill President & Chief Executive Officer Chief Financial Officer Senior Vice President, General Counsel, Marketing Chief Compliance Officer Bella Neufeld Shari Hubbell Neil Abhyankar Ben Viering Rakesh Ahuja Vice President, Senior Director, Vice President, Vice President, Information Vice President, Operations Customer Relations Sales Systems & Architecture Quality & Regulatory © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 27
Leading provider of custom research and GMP-grade reagents ready to support our customers as they scale We are successfully executing on our long-term growth plan, having increased our Clinical Solutions customer 1 base from 13 to 60 over the past five years We believe we are poised to drive significant long-term value for shareholders with these targets: • Sustainable 20-25% Revenue Growth Research-grade reagents provide a diverse, • 60-65% Gross Margin predictable, and growing foundation, with over 3,000 customers and a compound annual growth rate for Lab • 25-30% Adjusted EBITDA Margin Essentials revenue in the low-double-digits since 2008 1 Clinical Solutions customers with >$5K spend per year © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 28
Q2:26 Financials
Q2:2026 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $12.2 • Total second quarter revenue up 18% compared to the same period in $10.3 18% y/y $2.4 prior year • Lab Essentials increased 18% $2.1 compared to the same period in prior year • Clinical Solutions increased 18% $9.2 compared to the same period in $7.8 prior year Q2:2025 Q2:2026 Lab Essentials Clinical Solutions Other © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 30
Q2:2026 Income Statement Highlights Gross Margin (%) Total OpEx ($M) $7.8 $7.4 40.1% 38.7% Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Diluted EPS ($) Adjusted EBITDA ($M) ($0.7) ($0.06) ($0.8) ($0.07) Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any qualified non-recurring items to EBITDA © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 31
Q2:2026 Cash Flow and Balance Sheet Highlights 1 Capital Expenditure ($M) Free Cash Flow ($M) ($0.6) ($2.3) $0.2 $0.1 Q2:2025 Q2:2026 Q2:2025 Q2:2026 Cash, Cash Equivalents, and Short-Term Investment was $17.4M as of June 30, 2026 1 Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, plant, and equipment © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 32
Quarterly Financial Trends 1 Gross Margin (%) Total OpEx ($M) $10.2 $8.0 $8.1 $7.9 $7.9 $7.8 $7.8 $7.5 $7.4 $7.2 40% 39% 34% 32% 31% 31% 30% 29% $8.9 $8.1 $8.0 $7.8 $7.8 $7.8 $7.5 $7.4 $7.4 24% $7.2 23% Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Recurring Non-Recurring 2 Adjusted EBITDA ($M) 3 Free Cash Flow ($M) ($0.7) ($0.8) ($0.6) ($0.8) ($1.6) ($1.5) ($1.8) ($2.0) ($2.4) ($2.3) ($2.4) ($2.5) ($2.6) ($3.0) ($3.6) ($3.2) ($4.3) ($3.8) ($5.0) ($6.7) Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 1 Gross Margin in Q3:24 excludes non-recurring, non-cash charges related to the expired and excess inventory ($2.8M) 2 3 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any qualified non-recurring items to EBITDA Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, plant, and equipment © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 33
2026 Outlook and Capital Runway GUIDANCE • Raising fiscal 2026 outlook for revenue and improving outlook for Free Cash Outflow • Anticipate total revenue of $45 million to $47 million for fiscal year ending December 31, 2026 (“2026”), up 14% y/y at the midpoint • Targeting Free Cash Outflow of less than $8 million for 2026 CAPITAL RUNWAY ASSUMPTIONS ADJUSTED • Estimate annualized revenue range of $52-57 million to achieve EBITDA POSITIVE Adjusted EBITDA break-even quarter before the end of 2027 QTR BY END OF • Expect sufficient liquidity to become cash flow positive with organic growth strategy, assuming: • Average low double-digit revenue growth 2027 • Average 70% contribution margin on additional revenue • Limited annual OpEx growth • ~$2 million per year of capital expenditure © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 34
Preliminary Q3:26 Financials
Preliminary Q3:26 Financial Results Q3 Highlights Metric Expected Result • Total revenue up 19% to 21% compared to the same period prior year Revenue $12.5M – $12.7M § Clinical Solutions revenue grew high double digits compared to the same period prior year, marking the highest revenue in over 3 years Gross Margin 36.0% – 38.0% § Steady and consistent high single-digit growth in Lab Essentials revenue compared to the same Adjusted EBITDA ($1.2M) – ($1.0M) period prior year • Gross margin expansion of 500-700 bps Cash & Short Term compared to same period prior year, driven $16.6M 1 Investments primarily by top-line growth • Adjusted EBITDA loss expected to improve by at least 25% compared to same period prior year driven by continued cost discipline 1 As of September 30, 2026 © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 36
Supplemental Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● All Rights Reserved ● October 2026 38
